Intercell (ICEL)

As of May 28, 2013, Intercell Ag was acquired by Valneva SE. Intercell AG, a biotechnology company, develops and commercializes novel immunomodulatory biologicals to prevent disease and reduce suffering worldwide. Its technology platforms include the patch-based vaccine delivery system and the proprietary human monoclonal antibody discovery system, eMAB. It offers Japanese Encephalitis, an inactivated vaccine indicated for active immunization for the prevention of disease caused by the Japanese Encephalitis virus in adults under the IXIARO and JESPECT brand names. Intercell AG’s Japanese Encephalitis vaccine is also completed Phase III clinical trial for pediatric use in non-endemic markets. The company’s product pipeline includes a Pseudomonas aeruginosa vaccine in Phase II/III clinical trial; Clostridium difficile vaccine in Phase Ib clinical trial; IC31 Tuberculosis vaccine in Phase II clinical trial; and Pandemic Influenza vaccine, a vaccine in Phase I clinical trial to prevent Pandemic influenza by combining the company’s vaccine enhancement patch with an injected vaccine. Its vaccines in pre-clinical stages comprise a vaccine candidate against Lyme borreliosis; and various therapeutic antibody programs focusing on influenza, human cytomegalovirus, and oncology. Intercell AG operates primarily in Austria, rest of Europe, and North America. The company has strategic partnerships with various pharmaceutical companies, including Novartis, Merck & Co., Inc., and Sanofi. Intercell AG is headquartered in Vienna, Austria.